SIGA’s Inflection Point: 19C Concluded, International Push Accelerates—But the Market Isn’t Buying
Q2 product revenues hit $38M and cash sits at $118M, yet the stock tumbled 30% in 90 days as investors weigh the US contract gap.
SIGA · Earnings Call · 2026-08-06
Strong Quarter, Falling Stock
SIGA Technologies (SIGA) delivered a robust Q2 2026, posting product related revenues of $38M, mostly from IV TPOXX delivered to the U.S. Strategic National Stockpile and oral TPOXX sold to two international customers. Management also reaffirmed a pristine balance sheet—“a cash balance of approximately $118 million and no debt” — Daniel Luckshire, Chief Financial Officer · 2026-08-06. Yet the market response has been brutal: the shares fell 30% in the last 90 days and remain 88% below their 2022 peak. The disconnect is telling. The headline beat masks a structural transition that investors are pricing as uncertainty: the completion of the 19C contract and the as‑yet‑unsigned follow‑on U.S. procurement agreement.
The End of the 19C Era
The second quarter marked the final delivery under the 19C contract that has anchored SIGA’s revenue since 2018. As CEO Diem Nguyen put it,
We continue to actively engage with the U.S. government across multiple levels on a new multiyear procurement contract.
But the tone on the call acknowledged the slowdown: progress has been slower than expected due to HHS restructuring and open leadership roles. “We believe the scale of change within HHS… have been a meaningful contributor to the slower pace toward this new contract.” — Diem Nguyen, Chief Executive Officer · 2026-08-06 This vacuum in U.S. federal demand is the crux of the market’s pessimism, even though management insists “we continue to believe the case for smallpox preparedness remains strong.” — Diem Nguyen, Chief Executive Officer · 2026-08-06
International Diversification Gains Urgency
With the 19C book now closed, the international business is no longer a side — it is the primary growth narrative. The quarter’s $13M of international sales included an Asia‑Pacific order and a first‑time European customer. The recent exclusive distribution agreement with Hikma MENA expands reach into a historically underrepresented region. Management’s language has shifted accordingly: “SIGA always has and will continue to focus on all of our customers, whether it's domestic or international.” — Diem Nguyen, Chief Executive Officer · 2026-08-06 More concretely, they disclosed that discussions with one international government are far enough along to target a new contract and delivery by March 2027. This is a meaningful escalation of the international thesis, but it remains lumpy and procedurally opaque.
Pipeline and Balance Sheet: Strength Amid Uncertainty
Beyond procurement, SIGA continues to invest in its future. The PEP program targets an FDA submission in the first half of 2027, and the pediatric formulation’s Phase I results are due by year‑end. On the financial side, the company carries no debt and a highly volatile revenue base — the same quarter a year ago saw nearly no product revenue. This lumpiness is structural, but the balance sheet gives ample runway. Management has historically used excess cash for annual special dividends, and the $118M war chest supports that commitment even as they explore acquisitions and in‑licensing. The key question is whether the U.S. contract gap will be bridged quickly enough to satisfy investors who have already paid for years of preparedness promises — and who now see preparedness spending compete with more immediate geopolitical priorities.In prior quarters, the same themes appeared, but with a different emphasis. In August 2025, CFO Dan Luckshire noted, “we have sold $135 million of oral TPOXX to 30 countries since 2020.” — Daniel J. Luckshire, Chief Financial Officer · 2025-08-06 That breadth is now being tested as SIGA pivots from a single large U.S. customer to a mosaic of sovereign orders. Whether the market rewards this shift or punishes the loss of revenue visibility is the crux of the next 12 months.